Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause: The PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study

NCT00401245 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00401245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00401245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause: The PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2006
Completion date
January 31, 2008
Enrollment
500 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

vasomotor symptoms